Butyrate Suppresses Glucose Metabolism of Colorectal Cancer Cells via GPR109a-AKT Signaling Pathway and Enhances Chemotherapy

Glycolysis inhibitors are promising therapeutic drugs for tumor treatment, which target the uniquely elevated glucose metabolism of cancer cells. Butyrate is a critical product of beneficial microbes in the colon, which exerts extraordinary anti-cancer activities. In particular, butyrate shows biase...

Full description

Bibliographic Details
Main Authors: Hong-Wei Geng, Feng-Yi Yin, Zhi-Fa Zhang, Xu Gong, Yun Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Molecular Biosciences
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2021.634874/full
_version_ 1818873599235194880
author Hong-Wei Geng
Feng-Yi Yin
Zhi-Fa Zhang
Xu Gong
Yun Yang
author_facet Hong-Wei Geng
Feng-Yi Yin
Zhi-Fa Zhang
Xu Gong
Yun Yang
author_sort Hong-Wei Geng
collection DOAJ
description Glycolysis inhibitors are promising therapeutic drugs for tumor treatment, which target the uniquely elevated glucose metabolism of cancer cells. Butyrate is a critical product of beneficial microbes in the colon, which exerts extraordinary anti-cancer activities. In particular, butyrate shows biased inhibitory effects on the cell growth of cancerous colonocytes, whereas it is the major energy source for normal colonocytes. Besides its roles as the histone deacetylases (HDACs) inhibitor and the ligand for G-protein coupled receptor (GPR) 109a, the influence of butyrate on the glucose metabolism of cancerous colonocytes and the underlying molecular mechanism are not fully understood. Here, we show that butyrate markedly inhibited glucose transport and glycolysis of colorectal cancer cells, through reducing the abundance of membrane GLUT1 and cytoplasmic G6PD, which was regulated by the GPR109a-AKT signaling pathway. Moreover, butyrate significantly promoted the chemotherapeutical efficacy of 5-fluorouracil (5-FU) on cancerous colonocytes, with exacerbated impairment of DNA synthesis efficiency. Our findings provide useful information to better understand the molecular basis for the impact of butyrate on the glucose metabolism of colorectal cancer cells, which would promote the development of beneficial metabolites of gut microbiota as therapeutical or adjuvant anti-cancer drugs.
first_indexed 2024-12-19T12:57:16Z
format Article
id doaj.art-b0e3d3d8804146ca95c30c158d52a309
institution Directory Open Access Journal
issn 2296-889X
language English
last_indexed 2024-12-19T12:57:16Z
publishDate 2021-03-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Molecular Biosciences
spelling doaj.art-b0e3d3d8804146ca95c30c158d52a3092022-12-21T20:20:21ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2021-03-01810.3389/fmolb.2021.634874634874Butyrate Suppresses Glucose Metabolism of Colorectal Cancer Cells via GPR109a-AKT Signaling Pathway and Enhances ChemotherapyHong-Wei GengFeng-Yi YinZhi-Fa ZhangXu GongYun YangGlycolysis inhibitors are promising therapeutic drugs for tumor treatment, which target the uniquely elevated glucose metabolism of cancer cells. Butyrate is a critical product of beneficial microbes in the colon, which exerts extraordinary anti-cancer activities. In particular, butyrate shows biased inhibitory effects on the cell growth of cancerous colonocytes, whereas it is the major energy source for normal colonocytes. Besides its roles as the histone deacetylases (HDACs) inhibitor and the ligand for G-protein coupled receptor (GPR) 109a, the influence of butyrate on the glucose metabolism of cancerous colonocytes and the underlying molecular mechanism are not fully understood. Here, we show that butyrate markedly inhibited glucose transport and glycolysis of colorectal cancer cells, through reducing the abundance of membrane GLUT1 and cytoplasmic G6PD, which was regulated by the GPR109a-AKT signaling pathway. Moreover, butyrate significantly promoted the chemotherapeutical efficacy of 5-fluorouracil (5-FU) on cancerous colonocytes, with exacerbated impairment of DNA synthesis efficiency. Our findings provide useful information to better understand the molecular basis for the impact of butyrate on the glucose metabolism of colorectal cancer cells, which would promote the development of beneficial metabolites of gut microbiota as therapeutical or adjuvant anti-cancer drugs.https://www.frontiersin.org/articles/10.3389/fmolb.2021.634874/fullbutyratecolorectal cancer cellglucose metabolismglycolysis inhibitionchemotherapy
spellingShingle Hong-Wei Geng
Feng-Yi Yin
Zhi-Fa Zhang
Xu Gong
Yun Yang
Butyrate Suppresses Glucose Metabolism of Colorectal Cancer Cells via GPR109a-AKT Signaling Pathway and Enhances Chemotherapy
Frontiers in Molecular Biosciences
butyrate
colorectal cancer cell
glucose metabolism
glycolysis inhibition
chemotherapy
title Butyrate Suppresses Glucose Metabolism of Colorectal Cancer Cells via GPR109a-AKT Signaling Pathway and Enhances Chemotherapy
title_full Butyrate Suppresses Glucose Metabolism of Colorectal Cancer Cells via GPR109a-AKT Signaling Pathway and Enhances Chemotherapy
title_fullStr Butyrate Suppresses Glucose Metabolism of Colorectal Cancer Cells via GPR109a-AKT Signaling Pathway and Enhances Chemotherapy
title_full_unstemmed Butyrate Suppresses Glucose Metabolism of Colorectal Cancer Cells via GPR109a-AKT Signaling Pathway and Enhances Chemotherapy
title_short Butyrate Suppresses Glucose Metabolism of Colorectal Cancer Cells via GPR109a-AKT Signaling Pathway and Enhances Chemotherapy
title_sort butyrate suppresses glucose metabolism of colorectal cancer cells via gpr109a akt signaling pathway and enhances chemotherapy
topic butyrate
colorectal cancer cell
glucose metabolism
glycolysis inhibition
chemotherapy
url https://www.frontiersin.org/articles/10.3389/fmolb.2021.634874/full
work_keys_str_mv AT hongweigeng butyratesuppressesglucosemetabolismofcolorectalcancercellsviagpr109aaktsignalingpathwayandenhanceschemotherapy
AT fengyiyin butyratesuppressesglucosemetabolismofcolorectalcancercellsviagpr109aaktsignalingpathwayandenhanceschemotherapy
AT zhifazhang butyratesuppressesglucosemetabolismofcolorectalcancercellsviagpr109aaktsignalingpathwayandenhanceschemotherapy
AT xugong butyratesuppressesglucosemetabolismofcolorectalcancercellsviagpr109aaktsignalingpathwayandenhanceschemotherapy
AT yunyang butyratesuppressesglucosemetabolismofcolorectalcancercellsviagpr109aaktsignalingpathwayandenhanceschemotherapy